AKTIS ONCOLOGY INC (AKTS)
Health Care · Targeted radiopharmaceuticals / radiotherapy oncology · NASDAQ
Clinical-stage oncology company developing miniprotein-conjugated alpha-particle radiopharmaceuticals targeting multiple solid tumors including urothelial cancer.
What AKTIS ONCOLOGY INC does
Aktis Oncology is a clinical-stage oncology company focused on developing targeted radiopharmaceuticals using proprietary miniprotein radioconjugate technology. The company's lead program targets Nectin-4 with [225Ac]Ac-AKY-1189, a miniprotein conjugated to the alpha-emitting radioisotope actinium-225, designed for treatment of locally advanced or metastatic urothelial cancer and other Nectin-4-expressing solid tumors. Aktis is building end-to-end supply capabilities and manufacturing infrastructure to support clinical development and potential commercial deployment of its radiopharmaceutical pipeline across multiple tumor types.
Themes: ["Radiopharmaceuticals / targeted radiotherapy","Oncology / cancer immunotherapy","Urothelial cancer","Solid tumor therapeutics","Alpha-emitting radioisotopes","Precision medicine / companion diagnostics"]
Fundamentals
- Price$28.42 as of 2026-07-09 close
- Market cap$1.6B as of 2026-07-10
- 1-year return-82.5% as of 2026-07-09 close
- Net margin-843.9% as of 2026-07-10
- Gross margin-11.6% as of 2026-07-10
- ROE-47.5% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+49.9% as of 2026-07-10
- Beta162.01 as of 2026-07-10
Key risks (from latest filing)
["Company is unprofitable and clinical-stage, with significant R&D expenses and no approved products; dependent on securing additional capital to fund development programs through clinical trials and potential regulatory approval.","Lead program [225Ac]Ac-AKY-1189 has not yet achieved clinical efficacy or regulatory approval; failure to demonstrate safety and efficacy in trials could result in program termination or significant delays.","Highly competitive field with established radiopharmaceutical programs from larger companies; must successfully differentiate miniprotein platform technology and expand beyond PSMA and somatostatin receptor targets to capture market opportunity."]
Competitors & peers
- Novartis (NVS) — radiopharmaceutical programs (PSMA, somatostatin receptor)
- Lantheus Holdings (LNTH) — radiopharmaceutical technology and imaging
- Telix Pharmaceuticals (TLXA) — targeted radiopharmaceuticals and imaging agents
- Seagen / Pfizer (PFE) — Padcev (nectin-4 targeting antibody-drug conjugate)
- Genmab (GMAB) — ADC and radiopharmaceutical programs
- Myriad Genetics (MYRG) — companion diagnostics and radiopharmaceuticals
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.